Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item5.02.Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

On April3, 2017, Justin Renz resigned as Executive Vice
President, Chief Financial Officer and Treasurer of Karyopharm
Therapeutics Inc. (the Company), effective April3, 2017. The
Company is commencing a search for a new chief financial officer.

On April3, 2017, the Company entered into a consulting agreement
(the Consulting Agreement) with Mr.Renz, to which Mr.Renz will
provide certain advisory and other consulting services to the
Company until January31, 2018 (or such earlier date upon which
the Consulting Agreement terminates in accordance with its
terms). As compensation for and during such services, certain of
Mr.Renzs outstanding and unvested equity awards shall continue to
vest according to their terms.

The foregoing summary of the Consulting Agreement is qualified in
its entirety by the full text of the Consulting Agreement, which
is filed herewith as Exhibit 10.1 and incorporated herein by
reference.

On April3, 2017, the Company also entered into a separation
agreement (the Separation Agreement) with Mr.Renz in connection
with his separation from service. to the terms of the Separation
Agreement and in consideration of a customary release of any
claims by Mr.Renz against the Company, Mr.Renz will be entitled
to severance payments in the aggregate amount of $278,250 to be
paid in semi-monthly installments for a period of nine months
beginning on the first payroll period after the Separation
Agreement becomes effective, continuation of healthcare benefits
for up to nine months and continued vesting of certain of
Mr.Renzs unvested equity awards during the term of the Consulting
Agreement. The foregoing summary of the Separation Agreement is
qualified in its entirety by the full text of the Separation
Agreement, which is filed herewith as Exhibit 10.2 and
incorporated herein by reference.

Effective April3, 2017, Michael Todisco, the Companys Vice
President, Finance and Assistant Treasurer will serve as the
Companys principal financial and accounting officer, on an
interim basis, until a successor for Mr.Renz has been identified.
Mr.Todisco, age 52, has over 25 years of experience in accounting
and financial reporting and has been employed by the Company as
its Vice President, Finance and Assistant Treasurer since
September 2016. Prior to joining the Company, from February 2014
to August 2016, Mr.Todisco served as Vice President, Controller
and then Vice President, Finance at Dicerna Pharmaceuticals Inc.
He served in vice president and controller positions at BG
Medicine, Inc. from June 2013 to February 2014 and Dusa
Pharmaceuticals, Inc. from May 2005 to May 2013. Earlier in his
career, Mr.Todisco held increasingly senior finance positions
with various publicly-held companies in the technology sector.
Mr.Todisco spent the first ten years of his career with Ernst
Young and KPMG LLP. Mr.Todisco received a Bachelor of Arts from
Colgate University and a Master of Science in Accounting from
Northeastern University.

Since the beginning of the Companys last fiscal year, the Company
has not engaged in any transaction in which Mr.Todisco had a
direct or indirect material interest within the meaning of Item
404(a) of Regulation S-K under the U.S. Securities Act of 1933.

Item9.01. Financial Statements and Exhibits.

The Exhibits to this Current Report on Form 8-K are listed in the
Exhibit Index attached hereto.

About Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. It lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. Its product pipeline includes Verdinexor (KPT-335), an oral SINE compound; KPT-9274, a dual p21-activated kinase 4 (PAK4)/Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, and KPT-350, a compound in development for the treatment of neurological disorders.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Recent Trading Information

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) closed its last trading session down -0.32 at 12.52 with 506,797 shares trading hands.